KRT18 and metastatic prostate carcinoma: This study aimed to characterize circulating hybrid cells co-expressing KRT18 (pan-cytokeratin) and PTPRC (CD45), termed KP_Pos, in metastatic prostate cancer (mPCa), and to assess their molecular features, tumor microenvironmental (TME) origins, and clinical relevance.